PLUR
Pluri Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$33.58M
P/E Ratio
—
EPS
$-3.31
Beta
0.72
52W High
$7.13
52W Low
$2.82
50-Day MA
$3.43
200-Day MA
$4.03
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
3.63
PEG Ratio
—
About Pluri Inc.
Pluri Inc. is a cutting-edge biotechnology company specializing in regenerative medicine and immunotherapy, with a strong emphasis on developing innovative cell-based therapies. Utilizing its proprietary technology platform, Pluri aims to tackle significant unmet medical needs in oncology and degenerative diseases. The company boasts a robust pipeline and strategic partnerships that position it to improve patient outcomes and capitalize on growth opportunities within the dynamic healthcare landscape. By focusing on the transformative potential of human cells, Pluri is establishing itself as a key player in the biotechnology industry, committed to advancing novel therapeutic solutions.
Fundamentals
| Revenue (TTM) | $1.34M |
| Gross Profit (TTM) | 544,000 |
| EBITDA | $-24.43M |
| Operating Margin | -3286.00% |
| Return on Equity | -1022.00% |
| Return on Assets | -50.60% |
| Revenue/Share (TTM) | $0.16 |
| Book Value | $-1.46 |
| Price-to-Book | 306.56 |
| Price-to-Sales (TTM) | 25.08 |
| EV/Revenue | 41.62 |
| EV/EBITDA | -1.28 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 7.00% |
| Shares Outstanding | $10.05M |
| Float | $4.53M |
| % Insiders | 43.11% |
| % Institutions | 13.47% |
Historical Volatility
HV 10-Day
33.09%
HV 20-Day
47.90%
HV 30-Day
47.93%
HV 60-Day
58.98%
HV Rank
4.4%
Volatility is currently contracting
Data last updated: 4/14/2026